Volpara share price slips despite milestone CEO change

Volpara shares have come under pressure despite the company's management update.

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Volpara shares are edging 2.25% lower to 87 cents
  • The company this morning announced the appointment of its first ever female CEO to lead the team
  • Teri Thomas will take over from Volpara founder Dr Ralph Highnam, who will become chief science and innovation officer

The Volpara Health Technologies Ltd (ASX: VHT) share price is backtracking this afternoon. This comes after the company announced the appointment of its first female CEO.

At the time of writing, the healthcare technology company's shares are down 2.25% to 87 cents. It's worth noting that despite falling today, its shares are up almost 22% in a month.

Volpara welcomes first female CEO

Volpara this morning revealed that Teri Thomas would take over the role of CEO from Dr Ralph Highnam.

Dr Highnam, who founded Volpara and has been CEO for 13 years, will move into the role of chief science and innovation officer to focus on developing the next wave of Volpara's innovative technology. Dr Highnam also held the title of director which he will also rescind.

Thomas, an experienced healthcare exceutive, will become the company's first female CEO. It marks a milestone move for the company as Thomas becomes "one of only a few women who are CEOs of tech companies listed on ASX", according to Volpara.

In Australia, despite making up 75% of the workforce, women represent only 45% of public hospital board chairs, 39% of private hospital CEO's, and 38% of state and federal chief medical or health officers, the company said.

While the formal change is not expected for another few months, an orderly transition of responsibilities is underway.

Volpara noted that Dr Highnam will continue to host investor presentations and the full-year results at the end of May.

Thomas, on the other hand, will be engaging with the sales and marketing teams in the United States as well as meeting strategic partners and customers.

The pair will work together on market communications and handover of the CEO duties.

Based in New Zealand, Thomas has an extensive history of executive management in the healthcare industry. This ranges from strategy and operations to running global sales and marketing teams.

Notably, Ms Thomas served 20 years at Epic, a leading healthcare software developer. A registered nurse with a master of science degree, Ms Thomas can add value on IT, clinical workflow, and patient experience.

Commenting on the move, outgoing CEO Dr Highnam said:

There's never been a more exciting time for Volpara Health.

I am turning commercial responsibility over to a gifted and experienced leader at a time where we are getting not just closer to early detection but prevention of breast cancer.

Teri's experience is ideal to help Volpara achieve its mission by reaching more patients in more ways.

Volpara share price snapshot

The past 12 months have been disappointing for investors, with the Volpara share price down almost 35%.

When looking at year-to-date, its losses are hovering at almost 17%.

Based on the current share price, Volpara commands a market capitalisation of around $219.18 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »